Skip to main content
Premium Trial:

Request an Annual Quote

Luminex, Partners HealthCare Collaborate on Biomarker, Assay Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex today announced a deal with healthcare system Partners HealthCare for the discovery of biomarkers and development of clinical assays.

Partners HealthCare Center for Personalized Genetic Medicine will develop molecular diagnostic assays based on biomarkers discovered within the integrated health system to be run on Luminex's xMAP platform.

Under the terms of the deal, the two partners will evaluate opportunities for assays developed and validated in PCPGM's CLIA-certified Laboratory for Molecular Medicine. Additional terms were not disclosed.

In an e-mail, a spokesman for Partners Healthcare said that it and Luminex are exploring all disease conditions, with a focus on oncology and cardiovascular disease.

Partners HealthCare owns several hospitals, mostly in the Boston vicinity, and was founded in 1994 by Brigham and Women's Hospital and Massachusetts General Hospital.

Patrick Balthrop, president and CEO of Austin, Texas-based Luminex, said in a statement, "[W]e are confident that our joint efforts will drive market innovation and important technology advancements that will help dramatically improve patients' lives in the years ahead."

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.